Increasing clarity on bone loss associated with antiretroviral initiation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Anti-retroviral Therapy-Induced Multiple Pathological Fractures in a HIV-Positive Young Female: A Case Report and Review of Literature.Journal of orthopaedic case reports · 2023
   Article
2. Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda.PloS one · 2021
   Article
3. Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in thepre- and post-HAART eras.Clinical rheumatology · 2020
   Review
4. Effects of maximal strength training on bone mineral density in people living with HIV and receiving anti-retroviral therapy: a pilot study.BMC sports science, medicine & rehabilitation · 2020
   Article
5. Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors.PloS one · 2020
   Article
6. Treatment of Human Immunodeficiency Virus Infection With Tenofovir Disoproxil Fumarate-Containing Antiretrovirals Maintains Low Bone Formation Rate, But Increases Osteoid Volume on Bone Histomorphometry.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
   Article
7. Emerging reverse transcriptase inhibitors for HIV-1 infection.Expert opinion on emerging drugs · 2018
   Review
8. Management of Reduced Bone Mineral Density in HIV: Pharmacological Challenges and the Role of Exercise.Frontiers in physiology · 2018
   Review
9. Complete manuscript Title: Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults.BMC infectious diseases · 2017
   Article
10. Alveolar bone in human immunodeficiency virus infection: is it changed by long-term antiretroviral therapy?International dental journal · 2017
    Article
11. Bone health and HIV in resource-limited settings: a scoping review.Current opinion in HIV and AIDS · 2016
    Article
12. Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.Biochemical and biophysical research communications · 2015
    Article
13. Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects.BMC infectious diseases · 2012
    Article
14. HIV: inflammation and bone.Current HIV/AIDS reports · 2012
    Review

Corrections and comments

• Comment on
  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.2011

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as